318. Treatment Outcomes of Prosthetic Joint Infections: An Internal Assessment of Adherence to Best Practice Guidelines
Session: Poster Abstract Session: Bone and Joint Infections
Thursday, October 4, 2018
Room: S Poster Hall
  • IDWeek Poster PJI FINAL.pdf (857.7 kB)
  • Background: The impact of prosthetic joint infections (PJI) on patient outcomes and health systems is extensive.  Patients with PJI may receive non-preferred antibiotic therapy due to ease of administration, cost, and drug interaction profile.  Our objective was to compare treatment of PJI to internal guideline-recommended therapy and assess treatment outcomes.

    Methods: To reduce heterogeneity of PJI treatment within a large, integrated health system, our antimicrobial stewardship program and orthopedic surgeons created an internal best-practice guideline for treatment of PJI based on published literature.  The guideline is organism and surgery specific (Figure 1).  Patients who had total knee arthroplasty (TKA) or total hip arthroplasty (THA) and subsequently developed PJI from July 2016 – June 2017 were identified retrospectively.  Recurrent infections were defined as recurrence of primary infections or new infections with other organisms. Rates between patients treated with guideline-concordant and guideline-discordant regimens were compared.

    Results: Among 36 TKAs complicated by PJI, fewer patients who received guideline-concordant therapy experienced recurrent infection than patients who received guideline-discordant therapy (1 of 16 patients [6.25%] v. 9 of 20 patients [45%], p=0.0219).  Among 25 THAs complicated by PJI, there was a trend towards fewer recurrent infections when patients received guideline-concordant therapy (2 of 12 patients [16.7%] v. 5 of 11 patients [45.5%], p=0.1775).  Common deviations from the guidelines included daptomycin use for methicillin-susceptible Staphylococcus spp. with implant retention due to ease of administration in outpatient settings and avoidance of rifampin due to tolerability or drug interactions.

    Conclusion: Deviation from treatment guidelines for PJI following TKA and THA may increase the risk of recurrent infection.  Barriers to utilizing guideline-recommended antibiotics in the outpatient setting should be addressed.  Institutions should develop internal consensus on PJI treatment with prospective surveillance.

    Figure 1. Treatment Recommendations for Staphylococcus spp. After Debridement and Implant Retention (DAIR) – One Element of the Comprehensive Internal Guideline

    Courtney Horvat, PharmD1, Margaret Cook, PharmD1, Katherine Torres, DO2, Thomas J. Dilworth, PharmD1 and Charles F. Brummitt, MD3, (1)Department of Pharmacy Services, Aurora Health Care, Milwaukee, WI, (2)Infectious Diseases Section, Aurora Health Care, Green Bay, WI, (3)Infectious Diseases Section, Aurora Health Care, Milwaukee, WI


    C. Horvat, None

    M. Cook, None

    K. Torres, None

    T. J. Dilworth, None

    C. F. Brummitt, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.